Lexicon Pharmaceuticals Sets Sights on Heart Trial Results, Diabetes Drug Resubmission in 2027
Lexicon Pharmaceuticals (LXRX) expects results from a heart trial and plans to resubmit sotagliflozin for type 1 diabetes in Q1 2027. The company aims for FDA approval in 2027, with safety data from the STENO1 study addressing DKA concerns. Lexicon also plans to market the drug for hypertrophic cardiomyopathy (HCM) separately, with its own pricing and branding.
How this was made

The 30-second read
Why it matters
The disclosed FDA concerns (DKA rates) and the company’s stated alignment on prospective safety criteria, plus STENO1’s reported DKA rate and exposure progress, update the regulatory risk framework for a potential 2027 approval.
Market read
Traders can reassess regulatory probability and timeline into 2027 based on the article’s specific FDA-aligned criteria and the reported STENO1 DKA rate progress.
What to watch
The article does not quantify the full dataset size beyond the exposure threshold, nor does it detail how FDA will weigh subgroup entry criteria or how the new HCM pricing/product-code strategy could affect near-term cash flows.
Background
Lexicon’s sotagliflozin is already approved for heart failure, and the company is pursuing additional indications including type 1 diabetes via a planned FDA resubmission under a new name (ZYNQUISTA).
Ticker impact
Lexicon plans to resubmit sotagliflozin (ZYNQUISTA) for type 1 diabetes in Q1 2027 after FDA concerns on DKA, using STENO1 safety data.
Likely modest upside bias if traders view the STENO1 DKA rate and exposure threshold as de-risking the resubmission, but volatility remains tied to FDA review outcomes.
The article provides specific FDA-aligned criteria (patient-years exposure threshold and DKA rate target) and states STENO1 has reached exposure and recorded a DKA rate near the untreated control, which can improve perceived regulatory odds ahead of the 2027 decision window.
Market effects
Reinforces the importance of prospective DKA safety datasets for SGLT2-class drugs in type 1 diabetes, potentially affecting sentiment around similar programs.
Limited direct regional impact; primarily US biotech regulatory and clinical-trial sentiment.
Moderate global relevance for diabetes drug development, but the catalyst is US FDA review timing.
Counterpoint
Even with STENO1 meeting exposure and showing a low DKA rate, FDA may still require additional prospective evidence or interpret endpoints more conservatively, delaying or limiting approval odds.
Key entities
- companyLexicon Pharmaceuticals
NASDAQ-listed biopharma planning a Q1 2027 FDA resubmission for type 1 diabetes using STENO1 safety data.
- drugsotagliflozin (ZYNQUISTA)
SGLT2 inhibitor being resubmitted for type 1 diabetes; FDA concerns center on diabetic ketoacidosis rates.
- clinical_studySTENO1
Third-party open-label study providing prospective safety data for the resubmission.
- regulatorFDA
Raised concerns about DKA rates and requested new prospective safety data for the resubmission.



